



## Original article

## Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs



Daniela Poli<sup>a,\*</sup>, Emilia Antonucci<sup>b</sup>, Elisa Vignini<sup>a</sup>, Lucia Martinese<sup>a</sup>, Sophie Testa<sup>c</sup>, Paolo Simioni<sup>d</sup>, Vittorio Pengo<sup>e</sup>, Pasquale Pignatelli<sup>f</sup>, Anna Falanga<sup>g</sup>, Lucilla Masciocco<sup>h</sup>, Doris Barcellona<sup>i</sup>, Antonio Ciampa<sup>j</sup>, Paolo Chiarugi<sup>k</sup>, Carmelo Paparo<sup>l</sup>, Walter Ageno<sup>m</sup>, Gualtiero Palareti<sup>b</sup>, START2 Registry investigators

<sup>a</sup> SOD Malattie Aterotrombotiche, Azienda Ospedaliero Universitaria-Careggi, Firenze, Italy

<sup>b</sup> Fondazione Arianna Anticoagulazione, Bologna, Italy

<sup>c</sup> UO Laboratorio Analisi, Centro Emostasi e Trombosi A O Istituti Ospitalieri di Cremona, Cremona, Italy

<sup>d</sup> UOSD Malattie Trombotiche ed Emorragiche, UOC Medicina Generale, AOU Padova, Italy

<sup>e</sup> Thrombosis Research Laboratory, Università degli Studi di Padova, Padova, Italy

<sup>f</sup> Centro Trombosi, Clinica Medica Policlinico Umberto I, Università la Sapienza Roma, Italy

<sup>g</sup> University Milan Bicocca, Dept. Medicine and Surgery, Monza and UOC SIMT, Hospital Papa Giovanni XXIII, Bergamo, Italy

<sup>h</sup> UOC Medicina Interna, Centro Controllo Coagulazione, Presidio Ospedaliero Lastaria, Lucera (Foggia), Italy

<sup>i</sup> Struttura Dipartimentale di Emostasi e Trombosi, AOU di Cagliari, Dipartimento di Scienze Mediche e Sanita' Pubblica, Università di Cagliari, Cagliari, Italy

<sup>j</sup> Centro Emostasi A.O.R.N. "SG Moscati", Avellino, Italy

<sup>k</sup> U.O. Analisi Chimico-Cliniche, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

<sup>l</sup> Patologia Clinica, Ospedale Maggiore Chieri (Torino), Italy

<sup>m</sup> Dipartimento di Emergenza e Accettazione, Centro Trombosi ed Emostasi, Ospedale di Circolo, Università dell'Insubria, Varese, Italy

## ARTICLE INFO

## Keywords:

Anticoagulation

Atrial fibrillation

Intracranial haemorrhage

Venous thromboembolism

## ABSTRACT

**Background:** Intracranial hemorrhage (ICH) is associated with severe prognosis and recurrent risk. This impacts on the decision to resume anticoagulation in atrial fibrillation (AF) or venous thromboembolism (VTE) patients. Purpose of our study is to evaluate the incidence rate of recurrent ICH in patients with AF or VTE resuming anticoagulation after a first ICH episode.

**Methods:** We report data of two cohorts of AF or VTE after a first ICH. The Vitamin K antagonist (VKA) cohort (166 patients) derives from CHIRONE Study, the direct oral anticoagulant (DOAC) cohort (178 patients) derives from START2-Register

**Results:** The clinical characteristics of the two cohort are similar with the exception of more prevalence of history of previous stroke/TIA in DOAC patients with respect to VKA ( $p = 0.02$ ) and serum creatinine levels  $> 1.5$  mg/dL in VKA patients with respect to DOAC ( $p = 0.0001$ ). The index ICH was spontaneous in 66.4% and in 33.7% among DOAC and VKAs cohort respectively ( $p = 0.0001$ ). During follow-up, 14 recurrent ICH were recorded; 9 (rate  $2.5 \times 100$  patient-years) in VKA and 5 (rate  $1.3 \times 100$  patient-years) in DOAC (Relative Risk 1.9; 95% CI 0.6–7.4;  $p = 0.2$ ). The univariate logistic regression analysis showed that patients with recurrent ICH were more frequently males, hypertensive, with a history of previous Stroke/TIA and older than patients without recurrence. VKA patients showed a higher risk of recurrence with respect to DOAC patients (OR 1.9; 95% CI 0.7–6.7).

**Conclusions:** A trend toward fewer ICH recurrences was detected among DOACs patients in comparison to the previously reported rate of patients on warfarin.

## 1. Introduction

Intracranial hemorrhage (ICH) is associated with high mortality and severe functional outcome [1]. ICH is frequently associated to

antithrombotic treatment and carries a substantial risk of recurrence. This risk impacts on the decision to resume anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).

The aging of the population in the Western countries causes a

\* Corresponding author: Centro Trombosi, Azienda Ospedaliero Universitaria Careggi, Viale Morgagni, 85–50134, Firenze, Italy.

E-mail address: [polida@aou-careggi.toscana.it](mailto:polida@aou-careggi.toscana.it) (D. Poli).

<https://doi.org/10.1016/j.ejim.2020.05.020>

Received 3 April 2020; Received in revised form 5 May 2020; Accepted 13 May 2020

Available online 07 June 2020

0953-6205/© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

growing number of patients suffering from AF or VTE, conditions that require long-term anticoagulation. The proposed tools for the stratification of bleeding risk are insufficient to reliably estimate the absolute bleeding rates, [2] and no specific bleeding stratification model has been implemented for ICH. Moreover, risk factors for ischemic stroke are also risk factors for ICH, and the definition of ‘shared risk factors’ have been proposed for age, hypertension, diabetes, renal failure, and previous stroke [3] that are associated with both conditions.

When ICH occurs, there is no solid evidence to drive the decision on whether anticoagulation should be resumed or not and the timing for resumption [4,5]. Available evidence only originates from observational studies, which included patients treated with vitamin K antagonists (VKAs) or antiplatelet drugs [6–13]. Presently, few data are available on patients treated with direct oral anticoagulants (DOACs) [14] and indicate a slight reduction in the risk of recurrent ICH, without reaching statistical significance. The lower risk of ICH in patients treated with DOACs compared to that of patients treated with warfarin has been consistently demonstrated in all the registrative studies, both in AF [15] and in VTE patients [16]. Therefore, the role of DOACs in patients who have suffered from ICH appeared widely promising to achieve lower ICH recurrent rates, although no direct evidence of this lower risk of recurrence exists.

The purpose of our study was to evaluate the incidence rate of recurrent ICH in a cohort of patients with AF or VTE who survived after a first episode of ICH and resumed anticoagulation with DOACs. We compared this cohort with a previously described cohort of patients [17] with AF or VTE who started anticoagulation with VKAs after a first episode of ICH.

## 2. Methods

In the present study we report data of two cohorts of patients who started anticoagulant treatment for atrial AF or VTE after the occurrence of a first ICH. The first cohort is derived from the previously published CHIRONE Study and includes AF and VTE patients on treatment with VKA (VKA cohort), the second cohort was obtained from the START2-Register and includes AF and VTE patients on treatment with DOAC (DOAC cohort).

The Cerebral Haemorrhage in Patients Restarting Oral Anticoagulant Therapy (CHIRONE) Study has been previously published [17]. The study included 267 patients who survived a first ICH and who were on VKA treatment, whatever the clinical indication for the therapy. The study was conducted in 27 Centers affiliated with the Italian Federation of Anticoagulation Clinics. In the CHIRONE Study 90 patients (33.7%) were on warfarin because carriers of prosthetic heart valves, 121 patients (45.3%) for AF, 45 patients (16.8%) for VTE, and 11 patients (4.2%) for other reasons. In this study only the 166 patients of the cohort of the CHIRONE study anticoagulated for AF and VTE were included.

As previously described, the START2-Register is an observational, multicenter, prospective cohort study that includes patients aged > 18 years, who start anticoagulation therapy, whatever the clinical indication for the therapy, the drug and dosage used [18].

All participating centers are asked to consecutively include patients who start anticoagulant treatment, for any indication and with any available drug. Baseline patient's clinical features are recorded by participants on web based case report forms, detailed methods for enrollment in the study has been previously published [18]. The registry has been approved on October 2011 ( $N = 142/2010/0/0ss$ ) by the Ethical Committee of the Institution of the Coordinating Member (Azienda Ospedaliero-Universitaria, Policlinico S. Orsola-Malpighi, Bologna, Italy), and by all Ethical Committees of participating centers. All patients gave their written informed consent before enrollment. The study is registered in Clinical Trials gov Identifier: NCT02219984; it is ongoing and actively recruiting.

Here we present the results of the cohort of patients included in the

START2 Register who started DOAC treatment for AF or for VTE after the occurrence of a first ICH. The patients of this cohort were enrolled in 15 Centres participating in the Registry, 9 of them participated also to the enrollment of the CHIRONE Study. For the purpose of the present analysis, data were collected from July 2013, when dabigatran was firstly marketed in Italy, to July 2019.

For both cohorts the decision about starting anticoagulation after ICH was the responsibility of the referring physician, on the basis of the thromboembolic risk estimate. To evaluate neurologic sequelae of the first ICH episode, modified Rankin Scale (mRS) score was assessed for each patient in both cohorts when anticoagulation was started after index ICH.

The follow-up started when an anticoagulant drug was resumed after the first episode of ICH and ended when a patient stopped being monitored by the Center, or at the occurrence of a recurrent ICH or death. Major bleedings (MB) different from ICH were defined as recommended by the International Society on Thrombosis and Haemostasis [19].

The major endpoint of the study was recurrent ICH during anticoagulant treatment.

### 2.1. Statistical analysis

Continuous variables are expressed as median with interquartile range (IQR). Categorical variables are expressed as frequencies and percentages. The number of bleeding events was expressed as percentage (with 95% confidence intervals [CI]) and incidence rate, calculated as the number of events per 100 patient/years of observation. Chi-squared test was used to compare proportions. Univariate analysis was used to explore the association among risk factors and recurrent ICH.  $P$  value < 0.05 was considered statistically significant. The SPSS software for Windows, version 25 (SPSS Inc.) and Stata, version 14 statistical software package (Stata Corp. College Station, Texas USA) were used for data processing. Anonymized study data can be made available to qualified investigators by contacting the first author

## 3. Results

We reported data of 344 survivors from ICH included in two cohorts. VKA cohort included 166 patients on oral anticoagulant treatment with warfarin for AF or VTE with a history of previous ICH. DOAC cohort included 178 patients who started oral anticoagulant treatment with one of the four available DOACs for AF or VTE after the occurrence of an episode of ICH. In particular, 48.3% of DOAC patients were treated with apixaban, 25.3% with rivaroxaban, 20.2% with dabigatran and 6.2% with edoxaban; 127 patients (71.3%) received the reduced dosage of the prescribed drug.

Clinical characteristics of patients are reported in Table 1. The two cohorts of patients had a similar median age (76.7 and 76.6 years) and similar gender distribution (males 61.8% and 60.8%, respectively). Similarly, several co-morbidities were equally represented in the two groups. The severity of the neurologic sequelae after the index event, performed by using the mRS, showed that about 60% of patients in the two cohorts had no symptoms or no significant disability (mRS 5–1), and patients with more severe neurological sequelae were equally represented in the two cohorts. Instead, the prevalence of history of previous stroke/TIA was 23.6% among DOAC patients and 16.3% in VKA patients. On the contrary, the prevalence of renal insufficiency (serum creatinine > 1.5 mg/dL) was 6.7% among DOAC patients and 25.9% among VKA patients.

The index ICH was spontaneous in 66.4% of cases among DOAC cohort and in 33.7% of cases among VKAs cohort. The site of the ICH was similar between the two cohorts (Table 2).

During follow-up, 14 recurrent ICH were recorded; 9 of them (rate  $2.5 \times 100$  patient-years) among AVK patients and 5 (rate  $1.3 \times 100$  patient-years) among DOAC patients. In the VKA cohort, 6 and 3

**Table 1**  
Characteristic of patients enrolled in the two cohort.

	VKA cohort	DOAC cohort	p
N, (%)	166	178	
Males	101 (60.8)	110 (61.8)	
Median age (IQR), years	76.7 (10.0;95.0)	76.6 (70.8;82.0)	
Età >75 years	99 (59.6)	103 (58.2)	
Follow-up (years)	362	390	
Median follow-up years (range)	1.6 (0.1–10.1)	1.9 (0.1–7.2)	
<i>Indication for OA</i>			
AF	121 (72.9)	123 (69.9)	
VTE	45 (27.1)	53 (30.1)	
<i>Co-morbidities</i>			
Hypertension	135 (81.3)	149 (83.7)	
Diabetes Mellitus	35 (21.2)	34 (19.1)	
Heart failure	21 (13.2)	37 (20.8)	0.04
Previous stroke/TIA	28 (16.3)	42 (23.6)	0.02
Creatinine > 1.5 mg/dl	37 (25.9)	12 (6.7)	0.0001
e-GFR <30 mL/min	14 (18.4)	7 (3.9)	0.0001
CAD/PAD	33 (21.6)	26 (14.6)	
Cancer	6 (3.7)	9 (5.0)	
Antiplatelet therapy	18 (10.8)	20 (11.2)	

VKA = vitamin K antagonist; DOAC = direct oral anticoagulant; TIA = transient ischemic attack.

CAD = coronary artery disease; PAD = peripheral artery disease.

**Table 2**  
Characteristics of index event.

	VKA cohort n, (%)	DOAC cohort n, (%)
<i>Type of index ICH</i>		
Spontaneous	163/166	152/178
Traumatic	55 (33.7)	101 (66.4)*
<i>Localization</i>		
Subdural hematoma	108 (66.3)	51 (33.6)
Subarachnoid	163/166	134/178
Intraparenchymal lobar	80 (49.1)	46 (34.3)
Intraparenchymal typical	26 (16.0)	18 (13.4)
Intraparenchymal all	42 (25.8)	33 (24.6)
<i>Modified Rankin score after the event</i>		
4	166	144/178
3	12 (7.2)	14 (9.7)
2	14 (8.5)	16 (11.1)
1–0	34 (20.6)	30 (20.8)
<i>Treatment of the cerebral bleeding</i>		
Surgical	19 (11.4)	33 (18.5)
Medical	147 (88.6)	145 (81.5)
<i>Type of drug at the index event</i>		
VKAs	152 (91.6)	77 (43.3)
DOACs	–	18 (10.1)
Antiplatelet	–	11 (6.2)
None	14 (8.4)	39 (21.9)
Unknown	–	33 (18.5)
<i>Type of drug during follow-up</i>		
Apixaban	–	86 (48.3)
Dabigatran	–	36 (20.2)
Edoxaban	–	11 (6.2)
Rivaroxaban	–	45 (25.3)
Warfarin (Target INR 2.5)	166	–
<i>Reduced dosage</i>		
All	–	127 (71.3)
Apixaban	–	63 (73.3)
Dabigatran	–	33 (91.7)
Edoxaban	–	8 (72.7)
Rivaroxaban	–	23 (51.1)

ICH = intracranial hemorrhage; VKA = vitamin K antagonist; DOAC = direct oral anticoagulant.

\*  $p = 0.001$ .

recurrent ICH occurred in patients whose index ICH was spontaneous or post-traumatic, respectively (Table 3). In DOAC cohort, all the recurrent ICH were recorded in patients with spontaneous index ICH. However, the recurrent rate was not statistically different between the

**Table 3**  
Characteristics of ICH recurrences.

	VKA cohort	DOAC cohort
Recurrent ICH (rate x100 pt-yrs)	9 (2.47)	5 (1.3)
Males, n (%)	7 (77.8)	3 (60.0)
Median Age (range) years	74 (56–85)	76.7 (60–89)
<i>Indication for OA</i>		
AF	6	4
VTE	3	1
Median Time from First ICH, years (range)	3.5 (0.1–32.5)	2.9 (2.5–4.3)
<i>Type of first ICH</i>		
Spontaneous	6 (66%)	5 (100%)
<i>Site of recurrent ICH</i>		
Intraparenchymal	3	2
Subdural hematoma	3	1
Subarachnoid	2	0
Unknown	1	2
<i>Modified Rankin score after recurrent ICH</i>		
5	3	1
4	1	0
3	0	1
2	2	1
1–0	3	2
Fatal events (rate x100 pt-yrs)	3 (0.82)	1 (0.26)
<i>Type of AO drug</i>		
Apixaban	–	3
Dabigatran	–	0
Edoxaban	–	0
Rivaroxaban	–	2
Warfarin	9	–
<i>Death, n(%)</i>		
	23 (13.8)	21 (11.8)

ICH = intracranial hemorrhage; OA = oral anticoagulation.

two cohorts (Relative Risk 1.9; 95% CI 0.6–7.4;  $p = 0.2$ ). Three out of the five patients who had recurrence in the DOAC cohort were on treatment with full dose DOAC.

DOAC patients showed 8 major bleedings not cerebral (5 gastrointestinal) (rate  $3.4 \times 100$  patient-years), instead no other major bleeding events occurred among VKA patients.

Overall mortality was 13.8% in VKA cohort and 11.8% in DOAC cohort (Table 3)

To evaluate the risk factors associated with recurrent ICH, a univariate logistic regression analysis was performed including both cohorts (Table 4). Patients with recurrent ICH were more frequently males, hypertensive, with a history of previous Stroke/TIA and older

**Table 4**  
Risk factors associated with recurrent ICH calculated in the whole population: univariate analysis.

	Patients without recurrence	Patientst with recurrence	OR	95% CI	p
N	330	14			
Male sex, N(%)	201 (60.9)	10 (71.4)	1.6	0.5–5.2	0.4
Patients with Age >75 y	192 (58.4)	10 (71.4)	1.8	0.5–5.8	0.3
Previous Stroke or TIA	66 (22.1)	4 (28.6)	1.4	0.4–4.6	0.6
Spontaneous ICH	147 (48.8)	9 (64.3)	1.9	0.6–5.7	0.3
Hypertension	271 (82.1)	13 (92.9)	2.6	0.3–20.9	0.3
Diabetes Mellitus	68 (21.1)	1 (7.7)	0.3	0.04–2.5	0.3
Heart Failure	57 (18.0)	1 (7.7)	0.4	0.05–3.0	0.4
CAD/PAD	56 (18.3)	3(23.1)	1.3	0.4–5.0	0.7
Active cancer	5 (1.5)	1 (7.7)	1.7	0.5–5.6	0.4
Serum creatinine > 1.5	47 (15.2)	2 (16.7)	1.1	0.2–5.2	0.9
Clearance < 30 mL/min	20 (8.2)	1(7.7)	1.6	0.2–13.7	0.7
DOAC treatment	173(52.4)	5(35.7)	1.9	0.7–6.0	0.2

ICH = intracranial hemorrhage; CAD = coronary artery disease; PAD = peripheral artery disease.

than patients without recurrence. However, none of these differences reached statistical significance. Patients treated with VKA showed a higher risk of recurrence with respect to patients treated with DOAC (OR 1.9)(95% CI 0.7–6.7;  $p = 0.2$ ).

#### 4. Discussion

In this study we report data of AF and VTE patients survived to a first episode of ICH who started or resume an anticoagulant drug after the hemorrhagic event. In particular, two cohorts of patients have been described, the first treated with VKA (in part previously described in the CHIRONE Study) and the second with DOACs. The main finding of our study is the lower rate of recurrent ICH among patients on DOACs with respect to patients on VKAs. To date only one study have been published reporting data on ICH recurrence in patients treated with DOACs [14]. However, this study was conducted on administrative data and no information were available on the quality of VKA treatment. Our findings are in agreement with the results of this study, confirming a comparable reduction of ICH recurrent risk.

The favorable safety profile of DOACs is well supported by clinical evidence and by guidelines for the treatment of both patients with AF [20] and VTE [21]. The lower risk of ICH in patients on treatment with DOACs compared to that of patients treated with warfarin has been widely demonstrated in all the registrative studies, both in AF [15] and in VTE patients [16]. Therefore, the role of DOACs in these patients appeared widely promising, even in the absence of direct evidence.

The resumption of anticoagulation is a frequent clinical challenge in routine practice and information on the risk of recurrence with and without antithrombotic treatment is still a controversial issue. Several studies reported data on the risk of recurrence during anticoagulant treatment [6–13].

In our study, the main difference between the two cohorts was the higher rate of spontaneous index ICH among DOAC patients in comparison to VKA patients. The present is an observational study and the decision about starting anticoagulation after ICH was the responsibility of the referring physician, on the basis of the thromboembolic and bleeding risk estimate. In our study, the index ICH event was spontaneous in more than 60% of patients in the DOAC cohort, in comparison to only 30% of the VKA cohort. The fear of ICH recurrence is higher in spontaneous ICH in comparison to patients who suffered from post-traumatic hemorrhage. Our findings could be related to a higher confidence of physicians on a lower cerebral bleeding risk of DOACs, leading to more frequent prescription of these in patients suffering from spontaneous ICH, nevertheless the scant information available. It should be noted that 9/15 (60%) Centres participating in the DOAC cohort have already participated to CHIRONE Study.

##### 4.1. Limitations and strength

This study has a significant limitation due to the observational design, leading to the selection of patients enrolled. Our patients were all survivors of a first ICH for whom the decision to start anticoagulation after ICH was taken. Therefore, no information on patients judged to be at very high bleeding risk or treated with antiplatelet drugs were recorded, and probably patients with severe neurologic sequelae were not included in the study. As a matter of fact, our patients had low mRS scores in more than 60% of cases, and only few patients had severe neurologic impairment. The second limitation is due to the low number of recurrent ICH recorded in our study. However, patients who restarted anticoagulation after ICH are rare and few data are available on this matter.

The strength of our study is the prospective and multicenter design, with long follow-up. Moreover, no patients were lost to follow-up. The follow-up started at the beginning of anticoagulation and periodic clinical evaluation have been performed. The information related to the acute phase of the index ICH have been derived from neurological

hospital records and reported in the case report form at the beginning of follow-up by the physician of the center.

#### 4.2. Conclusion

In conclusion, a trend toward fewer ICH recurrences was detected among patients who resumed anticoagulation with DOACs after intracranial hemorrhage in comparison to the previously reported rate of patients treated with warfarin. The results of ongoing randomized clinical trials will provide more reliable data on this issue.

#### Ethics approval

Institutional Review Boards of the participating centres.

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

#### List of participating centers

- Daniela Poli, Elisa Vignini, Lucia Martinese, Eleonora Camilleri, SOD Malattie Aterotrombotiche, Azienda Ospedaliero Universitaria-Careggi, Firenze
- Sophie Testa, Oriana Paoletti, UO Laboratorio Analisi, Centro Emostasi e Trombosi A O Istituti Ospitalieri di Cremona, Cremona
- Giuliana Guazzaloca, Benilde Cosmi, Ludovica Migliaccio, UO di Angiologia e Malattie Coagulazione, AOU S. Orsola-Malpighi, Bologna
- Paolo Simioni, Elena Campello, UOSD Malattie Trombotiche ed Emorragiche, UOC Medicina Generale, AOU Padova
- Vittorio Pengo, Thrombosis Research Laboratory, Università degli Studi di Padova, Padova;
- Walter Ageno, Samuela Pegoraro, Dipartimento di Emergenza e Accettazione, Centro Trombosi ed Emostasi, Ospedale di Circolo, Università dell'Insubria Varese
- Pasquale Pignatelli, Daniele Pastori, Centro Trombosi, Clinica Medica Policlinico Umberto I°, Università la Sapienza Roma
- Anna Falanga <sup>(1, 2)</sup>, Laura Russo <sup>(2)</sup>, <sup>1</sup>University Milan Bicocca, Dept. Medicine and Surgery, Monza; <sup>2</sup>UOC SIMT, Hospital Papa Giovanni XXIII, Bergamo
- Lucilla Masciocco, UOC Medicina Interna, Centro Controllo Coagulazione, Presidio Ospedaliero Lastaria, Lucera (Foggia)
- Doris Barcellona, Struttura Dipartimentale di Emostasi e Trombosi, AOU di Cagliari, Dipartimento di Scienze Mediche e Sanita' Pubblica, Università' di Cagliari
- Antonio Ciampa, Centro Emostasi A.O.R.N. "SG Moscati", Avellino
- Paolo Chiarugi, U.O. Analisi Chimico-Cliniche, Azienda Ospedaliero Universitaria Pisana, Pisa
- Carmelo Paparo, Patologia Clinica, Ospedale Maggiore Chieri (Torino)
- Eugenio Bucherini, Juliana Mourao Pires, SS Medicina Vascolare - Angiologia, Ospedale Civile Faenza/Ravenna - AUSL Romagna, Faenza (Ravenna)
- Marco Marzolo, UOC Medicina Interna, Ospedale di Rovigo

#### CRediT authorship contribution statement

**Daniela Poli:** Conceptualization, Formal analysis, Writing - original draft. **Emilia Antonucci:** Formal analysis, Writing - original draft. **Elisa Vignini:** Data curation. **Lucia Martinese:** Data curation. **Sophie Testa:** Data curation. **Paolo Simioni:** Data curation. **Vittorio Pengo:** Writing - review & editing. **Pasquale Pignatelli:** Data curation. **Anna Falanga:** Data curation. **Lucilla Masciocco:** Data curation. **Doris Barcellona:** Data curation. **Antonio Ciampa:** Data curation. **Paolo Chiarugi:** Data curation. **Carmelo Paparo:** Data curation. **Walter Ageno:** Writing - review & editing. **Gualtiero Palareti:** Writing - review & editing.

## Declaration of Competing Interest

None declared

## References

- [1] Hemphill JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the american heart association/american stroke association. *Stroke* 2015;46:2032–60.
- [2] Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2) HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. *J Am Coll Cardiol* 2012;60:861–7.
- [3] McGrath ER, Kapral MK, Fang J, Eikelboom JW, Conghaile A, Canavan M, O'Donnell MJ. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation? *Stroke* 2012;43:2048–54.
- [4] Li YG, Lip GYH. Anticoagulation resumption after intracerebral hemorrhage. *Curr Atheroscler Rep* 2018;20:32.
- [5] Kuramatsu JB, Huttner HB. Management of oral anticoagulation after intracerebral hemorrhage. *Int J Stroke* 2019;14:238–46.
- [6] Witt DM, Clark NP, Martinez K, Schroeder A, Garcia D, Crowther MA. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. *Thromb Res* 2015;136:1040–4.
- [7] Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA* 2015;313:824–36.
- [8] Nielsen PB, Larsen TB, Skjoth F, Forst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. *Circulation* 2015;132:517–25.
- [9] Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. *Circulation* 2016;133:1540–7.
- [10] Park YA, Uhm JS, Pak HN, Lee MH, Joung B. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. *Heart Rhythm* 2016;13: 1794–802.
- [11] Ottosen TP, Grijota M, Hansen ML, Brandes A, Damgaard D, Husted SE, Johnsen SP. Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. *Stroke* 2016;47: 1837–43.
- [12] Nielsen PB, Larsen TB, Skjoth F, Lip GY. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. *JAMA Intern Med* 2017;177: 563–70.
- [13] Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. *Neurology* 2017;89: 687–96.
- [14] Nielsen PB, Skjoth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. *Stroke* 2019;50: 939–46.
- [15] Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;383: 955–62.
- [16] van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. *Blood* 2014;124: 1968–75.
- [17] Poli D, Antonucci E, Dentali F, Erba N, Testa S, Tiraferri E. Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. *Neurology* 2014;82: 1020–6.
- [18] Antonucci E, Poli D, Toso A, Pengo V, Tripodi A, Magrini N. The italian start-register on anticoagulation with focus on atrial fibrillation. *PLoS ONE* 2015;10:e0124719.
- [19] Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005;3: 692–4.
- [20] Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;33: 2719–47.
- [21] Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP. ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the european society of cardiology (ESC). *Eur Respir J* 2019;54: 2019.